The BD COR™ System is a fully automated and integrated high-throughput diagnostic system2 that enhances both laboratory operations and patient management with advanced molecular diagnostic capabilities.1-2


The BD COR™ System consists of a central preanalytical module (BD COR™ PX instrument) that can be configured with each of two different analytical modules (BD COR™ GX and BD COR™ MX instruments).1

H2 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Placeholder

H3 Lorem ipsum dolor sit amet, consetetur

Diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Placeholder

H3 Lorem ipsum dolor sit amet, consetetur

Diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Placeholder

H3 Lorem ipsum dolor sit amet, consetetur

Diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Learn more about the three individual instruments that make up the life inside of the BD COR™ System


The PX instrument automates preanalytical steps to simplify and standardize workflows, reducing staff interaction and maximizing walk-away time.1,2

Integrated automation
  • Less than 15 minutes to fully load instrument for testing.
  • Specimens are sorted and delivered automatically to analytical modules.1
  • Barcode-driven chain of custody allows for full traceability and follow-up testing.1
High capacity
  • ~480 BD SurePath™ LBC vials.2
  • ~2100 BD Collection Devices for IVD assays.
  • ~350 Hologic PreservCyt® LBC primary vials.

The GX instrument is used in conjunction with the PX instrument.1

The GX instrument automates the BD Onclarity™ HPV Assay, the only FDA-approved assay that offers extended genotyping and identification of HPV 31.5,7,8

Extended genotyping
  • BD Onclarity™ HPV Assay run on BD COR™ System enabled by the BD Synapsys™ Informatic Solution can track genotype-specific high-risk HPV persistence, the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotypes.5,8-11
HPV31
  • BD Onclarity™ HPV Assay run on BD COR™ System can individually identify HPV 31, which poses a higher risk for cervical precancer as compared to HPV 18.5,12
Diagnostic coverage
  • BD Onclarity™ HPV Assay is FDA-approved for all 3 cervical cancer screening paradigms.5
Collection device versatility
  • BD Onclarity™ HPV Assay can be used to test specimens placed in a BD SurePath™ vial or Hologic PreservCyt® Solution.
Maximize throughput and minimize hands-on time:
  • With just 1 operator and 2 instrument interventions, a laboratory can get 330 results from one 8-hour shift.1
  • Achieve 180 HPV results with extended genotyping without user intervention.2
  • Spend less than 15 minutes to fully load consumables and reagents.6
  • Get back more than 7 hours in your day through walk-away time at maximum throughput.1
The MX instrument is used in conjunction with the PX instrument.1

The MX instrument automates the BD CTGCTV2 FDA-cleared assay that detects the 3 most prevalent non-viral STIs in one fully automated run.3,13,14

3-in-1 assay
  • The BD CTGCTV2 assay ident ifies TV in addition to GC and CT, an infection with an estimated number of new cases greater than the combined number of new cases of CT, GC and syphilis in the US.13,3
High specificity
  • The BD CTGCTV2 assay includes dual gene targets for GC, which maximizes the assay specificity and eliminates the need for separate confirmatory test for positive results.3,14
Sample Flexibility
  • The BD CTGCTV2 assay can be run on patient-or clinician-collected vaginal swabs**, on urine samples or on LBC media.3
Maximum throughput, minimal time at the instrument:
  • Get 1248 results f rom one 8-hour shift with a dual MX instrument configuration.15,***
  • Spend about 15 minutes to fully load the machine.15
  • Save more than 7 hours of walk-away time at maximum throughput.15

Discover what the life inside of the BD COR™ System can do for your lab

  

Automates preanalytical steps to simplify and standardize workflows, reducing staff interaction and maximizing walk-away time.1,2

  

Provides complete sample management and is the only high-throughput fully integrated preanalytical and analytical system on the market.1,2

  

Uses multiplex PCR assay design and requires less than 1 hour of daily hands-on time for the full BD COR™ workflow. 2,3,6

  

Provides integrated automation on an expanding list of high-demand molecular assays in women's health and infectious disease testing.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit sed.

  • Lorem ipsum dolor sit amet,
  • consectetur adipiscing elit, sed do eiusmod
  • Habitant morbi tristique senectus et netus et
  • Lorem ipsum dolor sit amet,
  • consectetur adipiscing elit, sed do eiusmod
  • Habitant morbi tristique senectus et netus et

Placeholder

PX instrument 

A preanalytical instrument that automatically vortexes, uncaps, aliquots, recaps and delivers samples to analytical instruments wit h batching and sorting capabilities to increase productivity and efficiency.1

Placeholder

GX instrument

An HPV analytical instrument that automates the BD Onclarity™ HPV Assay with extended genotyping, requiring minimum interactions per shift at maximum throughput.1,5,6

Placeholder

MX instrument

A molecular diagnostics analytical instrument for integrated automation of an expanding list of high-demand, essential assays in women's health and infectious disease testing.3

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

Let's have a conversation

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>

Placeholder

H3 Lorem ipsum dolor sit amet,

  • Lorem ipsum dolor sit amet,
  • consectetur adipiscing elit, sed do eiusmod
  • Habitant morbi tristique senectus et netus et
  • Lorem ipsum dolor sit amet,
  • consectetur adipiscing elit, sed do eiusmod

Placeholder

H3 Lorem ipsum dolor sit amet,

  • Lorem ipsum dolor sit amet,
  • consectetur adipiscing elit, sed do eiusmod
  • Habitant morbi tristique senectus et netus et
  • Lorem ipsum dolor sit amet,
  • consectetur adipiscing elit, sed do eiusmod

Placeholder

The PX instrument automates preanalytical steps to simplify and standardize workflows, reducing staff interaction and maximizing walk-away time.1,2

Integrated automation

  • <15 minutes to fully load instrument for testing.
  • Specimens are sorted and delivered automatically to analytical modules.1
  • Barcode-driven chain of custody allows for full traceability and follow-up testing.1

High capacity

  • ~480 BD SurePath™ LBC vials.2
  • ~2100 BD Collection Devices for IVD assays.
  • ~350 Hologic PreservCyt® LBC primary vials

Placeholder

The GX instrument is used in conjunction with the PX instrument.1

The GX instrument automates the BD Onclarity HPV Assay, the only FDA-approved assay that offers extended genotyping and identification of HPV 31.5,7,8

Extended genotyping

  • BD Onclarity HPV Assay run on BD COR™ System can track genotype-specific high-risk HPV persistence, the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotypes.5,8-11

HPV31

  • BD Onclarity HPV Assay run on BD COR™ System can individually identify HPV 31, which poses a higher risk for cervical precancer as compared to HPV 18.5.12

Diagnostic coverage

  • BD Onclarity HPV Assay is FDA-approved for all 3 cervical cancer screening paradigms.5

Maximize throughput and minimize hands-on time:

  • With just 1 operator and 2 instrument interventions, a laboratory can get 330 results f rom one 8-hour shift.1
  • Achieve 180 HPV results with extended genotyping without user intervention. 2
  • Spend less than 15 minutes to fully load consumables and reagents.6
  • Get back more than 7 hours in your day through walk-away time at maximum throughput.1

Placeholder

The MX instrument is used in conjunction with the PX instrument.1

The MX instrument automates the BD CTGCTV2 FDA-cleared assay that detects the 3 most prevalent non-viral STIs in one fully automated run.3,13,14

3-in-1 assay

  • The BD CTGCTV2 assay ident ifies TV in addition to GC and CT, an infection with an estimated number of new cases greater than the combined number of new cases of CT, GC and syphilis in the US.13,3

High specificity

  • The BD CTGCTV2 assay includes dual gene targets for GC, which maximizes the assay specificity and eliminates the need for separate confirmatory test for positive results.3,14

Sample Flexibility

  • The BD CTGCTV2 assay can be run on patient-or clinician-collected vaginal swabs**, on urine samples or on LBC media.3

Maximum throughput, minimal time at the instrument:

  • Get 1248 results f rom one 8-hour shift with a dual MX instrument configuration.15
  • Spend about 15 minutes to fully load the machine.15
  • Save more than 7 hours of walk-away time at maximum throughput.15

H2 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod magus

Placeholder

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

Store Tab

360° rotation knob is effectively sized, contoured and located to enable easy instrument rotation.

360° rotation knob is effectively sized

360° rotation knob is effectively sized

360° rotation knob is effectively sized

More product details

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>

H2 Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit.

Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>
Bibendum est ultricies integer quis auctor elit.>>

The BD Onclarity™ HPV Assay has recently gained FDA approval for use with vaginal specimens self-collected in a healthcare setting when cervical specimens cannot otherwise be obtained, making it the first and only HPV test with extended genotyping to be FDA-approved for self-collection.5†

Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.5

H3 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit sed. Magna eget est lorem ipsum dolor sit amet.

H3 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Habitant morbi tristique senectus et netus et malesuada fames. Bibendum est ultricies integer quis auctor elit sed. Magna eget est lorem ipsum dolor sit amet.

Comprehensive capabilities. Breakthrough performance.


Let's have a conversation

REFERENCES

*The PX instrument is integrated with ananalytical instrument.
**Patient collection takes place in a healthcare setting.

HPV, human papillomavirus: LBC, Liquid-based cytology

1. Taylor SN et al.Expert Rev Mo/ Diagn. 2021:21(3):333-42. 2. Ejegod OM et al.Am JC/in Pathol. 2021:1-9. 3.BD CTGCTV2 for BO COR™ System Product Insert [L012506). 4. Taylor Set al.J Mo/ Diagn. 2022:24(5):485-93. 5. BD Onclarity™ HPV Assay for the BD COR™ System Product Insert [L011461). 6. HTOI-21-0406 BD COR™ Hands-On Setup Time. 7. Salazar KL et al. J Am Soc Cytopathol. 2019:8(5):284-92. 8. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1-13. 9. Elfgren Ket al.Am J Obstet Gyneco/. 2017;216(3):264.e1-7. 10. Radley 0 et al. Hum Vaccin Immunother. 2016;12(3):768-72. 11.Bodily J and Laimins LA.Trends Microbial. 2011;19(1):33- 9. 12.Stoler MH et al. Gynecol Oneal. 2019;153(1):26-33. 13. Centers for Disease Control and Prevention. Sexually Transmitted Diseases (STOs).Available at: https:J/www.cdc.gov/stdlstatistics/preva/ence-2020-at-a-glance.htm. Last updated 25 Jan2021. Accessed 18 Feb 2022. 14. VanDer Pol Bet al. SexTransm Dis. 2021;48(2):134-40. 15.HTMI-22-0004 BO COR'" MX Throughput Capping.

BD is committed to keeping your personal data protected and secure. More information on how we protect your personal data can be found in our privacy statement and our cookie policy.

Contact us | Unsubscribe | My profile